Zoetis(US:ZTS) Yahoo Finance·2025-09-23 23:02Company Overview - Zoetis Inc. (NYSE:ZTS) is a global leader in animal health, focusing on medicines, vaccines, and diagnostics for livestock and companion animals, achieving consistent revenue growth of approximately 4.2% year over year [2]. Financial Performance - The company demonstrates strong financial resilience with a return on equity exceeding 55%, free cash flow surpassing $2.2 billion, and a dividend yield of around 1.3%, supported by a conservative payout ratio [2]. - Zoetis reported quarterly earnings per share of $1.76, exceeding the estimate of $1.62, and set full-year guidance at $6.30–$6.40 [4]. Key Developments - A significant collaboration with Blacksmith Medicines aims to develop new antibiotics to combat antimicrobial resistance in veterinary care, positioning Zoetis at the forefront of this global challenge [3]. - The company is expanding its presence in the companion animal market, with its arthritis therapy for cats, Portela (relfovetmab), receiving a positive opinion from the European Medicines Agency in September 2025, highlighting its commitment to addressing unmet needs in pet health [3].